SCYX - Biotech News Recap: Catalyst Pharmaceuticals Hit By Surprise From FDA But Should Recover With Coming Catalysts

Catalyst Pharmaceuticals (CPRX) - As I'm writing this, the stock has lost 40% of its value in a single day after news came that the FDA approved Ruzurgi from Jacobus Pharma for LEMS (Lambert-Eaton myasthenic syndrome) patients age six to less than 17 years of age. This is the first approval for pediatric LEMS patients, as Catalysts' Firdapse is approved only for use in adults.

Some patients and legislators likely feel the FDA made the right move here, considering that the drug (also known as 3,4-diaminopyridine or 3,4-DAP) was available for free over